Olema appoints Scott Garland to board of directors with extensive launch experience

Olema Pharmaceuticals, Inc.

Scott Garland appointed to Olema's Board as Class III director effective Oct 16, 2023.
Garland brings >30 years biopharma experience; former CEO of PACT Pharma and Portola.
He received initial equity grants: 21,520 shares (option) vesting over 3 years, and 14,347 shares (option) vesting by 2024 annual meeting.
Also receives annual cash retainer of $40,000 and additional $6,000 for Compensation Committee service.
Board cites his commercial expertise as crucial as palazestrant enters Phase 3.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Garland

Class III Director

OLMA · Olema Pharmaceuticals, Inc.

Effective: 2023-10-16
Filed: October 18, 2023, 7:59 PM ET

appointed Scott Garland to the Board as a Class III director, effective October 16, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Garland was appointed as Class III Director at Olema Pharmaceuticals, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

appointed Scott Garland to the Board as a Class III director, effective October 16, 2023

View on SEC.gov

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-016518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.